Medicinal Cannabis Delivery Methods

NanaBis Medicinal Cannabis Delivery Methods Clinical Review

Medicinal Cannabis Delivery Methods

Type: Technical Documents

Language: English

Version # 1


Online reference list


1. Millar, S.A. et al. (2018) A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 9, 1365.

2. Russo, E.B. (2019) Cannabis and Pain. Pain Med 20 (11), 2083-2085.

3. Ohlsson, A. et al. (1986). Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed. Environ. Mass Spectrom. 13(2), 77–83. doi: 10.1002/bms.1200130206.

4. Grotenhermen, F. (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42 (4), 327-60.

5. Almog, S. et al. (2020) The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain 24 (8), 1505-1516.

6. Hunault, C.C. et al. (2008) Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl) 201 (2), 171-81.

7. Newmeyer, M.N. et al. (2016) Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clin Chem 62 (12), 1579-1592.

8. Abrams, D.I. et al. (2007) Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 82 (5), 572-8.

9. Huestis, M.A. et al. (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16 (5), 276-82.

10. Lucas, C.J. et al. (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84 (11), 2477-2482.

11. Robson, P. (2011) Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10 (5), 675-85.

12. Schlag, A.K. et al. (2021) Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. Journal of Psychopharmacology 00(0), 1-13. doi:10.1177/0269881120986393.

13. Adapa, S. et al. (2020) Cannabis Vaping–Induced Acute Pulmonary Toxicity: Case Series and Review of Literature. Journal of Investigative Medicine High Impact Case Reports 8, 1-8. doi: 10.1177/2324709620947267.

14. Sarafian, TA. et al (1999). Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20(6),1286-93. doi:

15. Gieringer, D. et al. (2004) Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics 4 (1), 7-27.

16. Clarke, S. et al. (2020) 219 Pilot clinical and pharmacokinetic study of a water soluble nanoparticle cannabis based medicine in advanced cancer with intractable pain. Asia Pac J Clin Oncol 16 (S8), 117-118.

17. Stott, C.G. et al. (2013) A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 69 (5), 1135-47.

18. Lichtman, A.H. et al. (2018) Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage 55 (2), 179-188.

19. Vitetta, L. et al. (2018) Route and Type of Formulation Administered Influences the Absorption and Disposition of Vitamin B12 Levels in Serum. J Funct Biomater 9 (1).

20. Therapeutic Goods Administration. Australian public assessment report for nabiximols. Available at:

21. Huestis, M.A. (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4 (8), 1770-804.

22. Clarke, S. et al. (2020) Pilot Clinical and Pharmacokinetic Study of Δ9-Tetrahydrocannabinol and Cannabidiol Oro-Buccal Spray in Advanced Cancer with Uncontrolled Pain. Authorea, 1-15.

23. Hosseini, A. et al. (2020) A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol 87 (4), 2070– 2077.

24. Scully, C. (2007) Cannabis; adverse effects from an oromucosal spray. Br Dent J 203 (6), E12; discussion 336-7.

25. SATIVEX (2020) AUSTRALIAN PRODUCT INFORMATION - SATIVEX (nabiximols). Retrieved from:

26. Stott, C.G. et al. (2013) A phase I study to assess the effect of food on the single-dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol 64 (4), 825-34.

27. Itin, C. et al. (2019) A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states. Expert Opin Drug Deliv 16 (10), 1031-1035.

28. Therapeutic Goods Administration. Australian public assessment report for nabiximols. Retrieved from:

29. Perucca, E. and Bialer, M. (2020) Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs 34 (8), 795-800.

30. Birnbaum, A.K. et al. (2019) Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 60 (8), 1586-1592.

31. Taylor, L. et al. (2018) A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs 32 (11), 1053-1067.

32. Lunn, S. et al. (2019) Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences. Cannabis and Cannabinoid Research 4, 255–264.

33. Crockett, J. et al. (2020) A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia 61 (2), 267-277.


Login as Doctor to View